pharmaceuticals

On Tuesday, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) agreed to acquire Chimerix Inc (NASDAQ:CMRX) for $8.55 per share in cash, representing a total consideration of approximately $935 million. Both companies have approved the transaction, and it is expected to close in the second...

Roche Holdings AG (OTC:RHHBY) released data Sunday on its Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH study for Xolair (omalizumab) for one or more food allergies. Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects...

On Thursday, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents. The biopharma company reported fourth-quarter sales of $59.9 million, up 33% year over year, almost in line with...

Walgreens Boots Alliance Inc (NASDAQ:WBA) shares traded higher Monday following reports that multiple lenders are preparing to back a potential buyout from Sycamore Partners. What To Know: Morgan Stanley, UBS and private lenders are reportedly putting together a $10 billion package to back Sycamore...

On Monday, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released results from an interim analysis of the ongoing APeX-P trial. The study centered on an oral granule formulation of once-daily Orladeyo (berotralstat) in pediatric patients. The patients have hereditary angioedema (HAE) aged 2 to 12...

On Thursday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide). The trial demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared...

Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) are duking it out for investor attention with fourth-quarter earnings being reported on Tuesday. Both pharmaceutical heavyweights have very different technical setups, leaving investors to wonder which stock will have the upper hand. Let's...

On Monday, Pfizer Inc (NYSE:PFE) revealed topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for...

As AbbVie Inc. (NYSE:ABBV) and Novartis AG (NYSE:NVS) prepare to report their fourth-quarter earnings before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants. While AbbVie is stuck in a stagnating trend, Novartis appears to have a stronger bullish...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with the Senate Finance Committee. While Kennedy’s tone in each back-and-forth varied, depending on the senator, it was...

On Wednesday, Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. The company says the findings contribute substantially to understanding the...

The U.S. Food and Drug Administration (FDA) issued a warning letter to Sanofi SA’s (NASDAQ:SNY) Genzyme Corporation regarding significant violations at its Framingham, Massachusetts, facility. After an inspection conducted between June 12 and July 9, 2024 the agency flagged major concerns...

On Tuesday, Valneva SE (NASDAQ:VALN) reported Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, Ixchiq. The vaccine showed a sustained 98.3% sero-response rate one year after the single vaccination. These results support and strengthen the pivotal data previously...

In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc (NASDAQ:VRTX), defending its stance that the company’s proposed fertility services program would breach anti-kickback laws. The program is tied to Vertex’s gene-editing...

On Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Scorpion Therapeutics, Inc’s PI3Kα inhibitor program STX-478. STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors....